We are very excited to share that Samsung Bioepis has been awarded for the ‘Biosimilar Initiative of the Year’ at the Global Generics & Biosimilars (GGB) Awards 2025. This is our fifth recognition from GGB Awards for all our efforts we’ve put in over the the year delivering quality-assured, safe and effective biosimilar medicines to patients worldwide.

This recognition highlights our strategic approach in the US, Europe, and Brazil. By closely assessing the distinct characteristics of each market, we have refined our commercial strategies to maximize the impact and accessibility of our biosimilar portfolio.

This year, the company has also been shortlisted as finalists for ‘Company of the Year,’ ‘Leader the Year,’ and ‘Business Development of the Year.’ Previously, Samsung Bioepis won the GGB Awards for ‘Company of the Year, Asia-Pacific’ in 2024, ‘Company of the Year, Asia-Pacific’, and ‘Regulatory Achievement of the Year’ in 2023, ‘Company of the Year, Asia-Pacific’ category in 2022 and ‘Biosimilar Initiative of the Year’ category in 2020.

The ‘Global Generics & Biosimilars Awards’ are presented annually by the international publishing company Citeline (previously Informa). This year, the event was held in Frankfurt, Germany on October 29, to celebrate the greatest achievements and innovations across the development, authorization, marketing and distribution of global off-patent pharmaceuticals and to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change.